Study analysis · Biological psychiatry · 2016
What if a $5 supplement could make your antidepressant work better?
Women with depression who took creatine along with their antidepressant felt better and showed improved brain energy and connections compared to those who took a placebo.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study gave some women with depression either a supplement or a fake pill, while both groups took the same antidepressant. It found that the supplement group felt better and their brains showed changes. But we can't say it works for everyone—just these women in this study.
What’s the bottom line?
Women with depression took a daily creatine pill along with their antidepressant. Their brains were scanned before and after 8 weeks to see if creatine changed anything.
How strong is this study?
This study was well-designed because it randomly assigned people and didn't tell them what they got, which helps avoid bias. But since we can't see the full details, we don't know if everything was done perfectly—so we should be a little careful trusting it too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
81 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=52)+4.6/20
- Follow-up+10/10
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The abstract explicitly states the study is a randomized, double-blind, placebo-controlled trial, which allows for causal inference. However, full methodology is not available, so potential biases (e.g., incomplete outcome reporting, selective analysis) cannot be fully assessed.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were disclosed in the provided text.
The study lacks any declared funding sources, conflict of interest statement, or author affiliations. While the methodology appears rigorous, the absence of transparency regarding funding or potential conflicts limits full assessment of independence.
Key takeaways
- 01
Women who took creatine felt better than those who took a placebo.
- 02
Their brains showed more N-acetylaspartate (a sign of healthy energy use) and stronger connections between key brain regions.
- 03
Yes — the improvement in brain markers and mood suggests creatine may help antidepressants work better by boosting brain energy and communication.
Practical takeaways
Women with depression on SSRIs like escitalopram might consider discussing creatine monohydrate (10g/day) as a potential augmentation with their doctor.
This study only included women, used a specific dose and duration, and full methodology was not available for verification.
low confidenceWhy this study matters
Creatine Boosts Mood in Depressed Women
In a study of 52 women with major depressive disorder taking escitalopram, those who added 10g/day of creatine showed greater improvement in depressive symptoms after 8 weeks than those on placebo. Neuroimaging showed increased prefrontal N-acetylaspartate and stronger rich club hub connectivity in the creatine group.
Creatine is a cheap, widely available supplement usually associated with athletes — now it might help treat depression by changing how the brain uses energy.
Depression Shows Up in the Brain’s Wiring
At baseline, women with MDD had lower levels of prefrontal N-acetylaspartate and weaker rich club hub connectivity compared to healthy women — suggesting depression has measurable biological signatures in brain energy and network structure.
This shows depression isn’t just 'in your head' — it’s tied to real, scan-detectable changes in brain biology, which can help reduce stigma.
Brain Energy Marker Rises with Creatine
After 8 weeks, the creatine group had significantly higher levels of prefrontal N-acetylaspartate — a biomarker linked to brain energy metabolism — than the placebo group, suggesting creatine may help restore cellular energy in depressed brains.
It’s rare to see a supplement directly linked to a specific brain chemistry change that correlates with mood improvement — this isn’t just anecdotal.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Women with depression took a daily creatine pill along with their antidepressant. Their brains were scanned before and after 8 weeks to see if creatine changed anything.
Research results
Women who took creatine felt better than those who took a placebo. Their brains showed more N-acetylaspartate (a sign of healthy energy use) and stronger connections between key brain regions.
What this means - more context
Yes — the improvement in brain markers and mood suggests creatine may help antidepressants work better by boosting brain energy and communication.
To evaluate whether creatine monohydrate augmentation enhances antidepressant response in women with major depressive disorder (MDD) by improving brain energy metabolism and structural network organization.
In a randomized, double-blind, placebo-controlled trial, 52 women with MDD receiving escitalopram were assigned to creatine or placebo augmentation. After 8 weeks, creatine augmentation led to greater improvement in depressive symptoms, increased prefrontal N-acetylaspartate, and enhanced rich club hub connectivity compared to placebo. Baseline reductions in these biomarkers were observed in MDD versus healthy women.
Methods Used
Randomized, double-blind, placebo-controlled trial with 52 women with MDD receiving escitalopram plus creatine (10g/day) or placebo. 34 participants underwent multimodal neuroimaging (proton MRS and DTI) at baseline and week 8. Age-matched healthy women (n=39) were also assessed.
Main Finding
Creatine augmentation significantly improved depressive symptoms compared to placebo, with greater increases in prefrontal N-acetylaspartate and rich club hub connectivity after 8 weeks.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Effect sizes and p-values not reported in abstract
- •Sample size and subgroup details limited to abstract
Practical Takeaways
Women with depression on SSRIs like escitalopram might consider discussing creatine monohydrate (10g/day) as a potential augmentation with their doctor.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study gave some women with depression either a supplement or a fake pill, while both groups took the same antidepressant. It found that the supplement group felt better and their brains showed changes. But we can't say it works for everyone—just these women in this study.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Explicitly described as randomized, double-blind, placebo-controlled trial
- Includes objective neuroimaging biomarkers
- Pre-post design with control group
Weaknesses
- Full methodology not available - based on abstract only
- No details on randomization procedure or allocation concealment
- Blinding success not reported
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Women with depression took a daily creatine pill along with their antidepressant. Their brains were scanned before and after 8 weeks to see if creatine changed anything.
Research results
Women who took creatine felt better than those who took a placebo. Their brains showed more N-acetylaspartate (a sign of healthy energy use) and stronger connections between key brain regions.
What this means - more context
Yes — the improvement in brain markers and mood suggests creatine may help antidepressants work better by boosting brain energy and communication.
To evaluate whether creatine monohydrate augmentation enhances antidepressant response in women with major depressive disorder (MDD) by improving brain energy metabolism and structural network organization.
In a randomized, double-blind, placebo-controlled trial, 52 women with MDD receiving escitalopram were assigned to creatine or placebo augmentation. After 8 weeks, creatine augmentation led to greater improvement in depressive symptoms, increased prefrontal N-acetylaspartate, and enhanced rich club hub connectivity compared to placebo. Baseline reductions in these biomarkers were observed in MDD versus healthy women.
Methods Used
Randomized, double-blind, placebo-controlled trial with 52 women with MDD receiving escitalopram plus creatine (10g/day) or placebo. 34 participants underwent multimodal neuroimaging (proton MRS and DTI) at baseline and week 8. Age-matched healthy women (n=39) were also assessed.
Main Finding
Creatine augmentation significantly improved depressive symptoms compared to placebo, with greater increases in prefrontal N-acetylaspartate and rich club hub connectivity after 8 weeks.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Effect sizes and p-values not reported in abstract
- •Sample size and subgroup details limited to abstract
Practical Takeaways
Women with depression on SSRIs like escitalopram might consider discussing creatine monohydrate (10g/day) as a potential augmentation with their doctor.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study gave some women with depression either a supplement or a fake pill, while both groups took the same antidepressant. It found that the supplement group felt better and their brains showed changes. But we can't say it works for everyone—just these women in this study.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Explicitly described as randomized, double-blind, placebo-controlled trial
- Includes objective neuroimaging biomarkers
- Pre-post design with control group
Weaknesses
- Full methodology not available - based on abstract only
- No details on randomization procedure or allocation concealment
- Blinding success not reported
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was well-designed because it randomly assigned people and didn't tell them what they got, which helps avoid bias. But since we can't see the full details, we don't know if everything was done perfectly—so we should be a little careful trusting it too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
81 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=52)+4.6/20
- Follow-up+10/10
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The abstract explicitly states the study is a randomized, double-blind, placebo-controlled trial, which allows for causal inference. However, full methodology is not available, so potential biases (e.g., incomplete outcome reporting, selective analysis) cannot be fully assessed.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were disclosed in the provided text.
The study lacks any declared funding sources, conflict of interest statement, or author affiliations. While the methodology appears rigorous, the absence of transparency regarding funding or potential conflicts limits full assessment of independence.